2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher

Pharmaceutical and Biotech Industry Overview - The pharmaceutical and biotech industry generally offers steady revenue performance due to the essential nature of medicines, but certain companies exhibit growth-like behavior when they innovate rapidly or operate in high-growth areas [1] Eli Lilly - Eli Lilly has experienced significant growth driven by its weight-loss drugs, Zepbound and Mounjaro, which generated $1.2 billion and $3.1 billion in revenue respectively in the most recent quarter [3] - The company is increasing production of these drugs, expecting a 60% rise in doses in the first half of this year compared to the same period last year [4] - Analysts predict the obesity drug market could reach $100 billion to $130 billion by 2030, positioning Eli Lilly for potential long-term stock price gains despite a 200% increase over the past three years [5] Vertex Pharmaceuticals - Vertex Pharmaceuticals is a global leader in cystic fibrosis treatment, with product revenue exceeding $2.7 billion in the recent quarter, driven by its top-selling drug Trikafta [6][7] - The company recently gained FDA approval for Alyftrek, a more efficacious and convenient once-daily cystic fibrosis treatment [6] - Vertex has applied for FDA approval of suzetrigine, a non-opioid candidate for moderate-to-severe acute pain, with a decision expected by the end of January, potentially representing a significant near-term catalyst [8] - If approved, suzetrigine could become a multibillion-dollar drug, offering a major long-term growth opportunity in the pain management market [9] - Vertex's stock has climbed 87% over the past three years, with further growth potential due to its innovative pipeline [10]